Skip to main content
Log in

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Elucidating the metabolic profile of anticancer agent panobinostat is essential during drug development. Disposition, metabolism, and excretion profiles were characterized using trace radiolabeled 14C-panobinostat in four patients with advanced cancer.

Methods

Oral 14C-panobinostat was administered and serial blood, plasma, and excreta samples were collected up to 7 days postdose for radioactivity and pharmacokinetic analyses. Metabolites in plasma and excreta were profiled using liquid chromatography (LC) with radiometric detection, and their structures elucidated using LC–tandem mass spectrometry.

Results

Radioactivity (≥87 %) was recovered in excreta within 7 days: 44–77 % dose recovery in feces and 29–51 % in urine. Circulating radioactivity was localized in plasma, with minor partitioning to blood. Minimal recovery in feces (<3.5 % of dose) suggested near-complete oral absorption. Maximum concentrations (median, 21.2 ng/mL; range, 13.4–41.5 ng/mL) were achieved within 1 h, and median (range) terminal half-life, apparent oral, and renal clearance was 30.7 h (27.6–33.2 h), 209 L/h (114–248 L/h), and 3.20 L/h (2.4–5.5 L/h), respectively. Approximately 40 metabolites were circulating in plasma, with biotransformation occurring primarily at the hydroxamic acid side chain and ethyl-methyl indole moiety. Metabolites derived from modification of the hydroxamic acid side chain were inactive for deacetylase inhibition.

Conclusions

Panobinostat and its metabolites were excreted in similar amounts through the kidneys and liver with good dose recovery. Panobinostat was rapidly absorbed and cleared primarily through metabolism. Over half of its clearance was attributed to non-CYP-mediated pathways. Thus, CYP-mediated drug–drug interactions with panobinostat are predicted to be minor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784

    Article  PubMed  CAS  Google Scholar 

  2. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233–241

    Article  PubMed  CAS  Google Scholar 

  3. Mateos MV, Spencer A, Taylor K, Lonial S, De La Rubia J, Facon T, Bengoudifa R, Klebsattel M, Hazell K, Bourquelot P, Rossi JF, Harousseau JL, Jagannath S, Wolf J, San Miguel J (2010) A phase IB study evaluating the combination of oral panobinostat (LBH589) with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Haematologica 95(Suppl 2):158, abstract 0390

    Google Scholar 

  4. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147:97–101

    Article  PubMed  CAS  Google Scholar 

  5. International Commission on Radiological Protection (ICRP) (1988) Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53 Ann. ICRP 18(1–4)

    Google Scholar 

  6. Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–413

    Article  PubMed  CAS  Google Scholar 

  7. Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601–612

    Article  PubMed  CAS  Google Scholar 

  8. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500–4510

    Article  PubMed  CAS  Google Scholar 

  9. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K, Yamamoto N (2012) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 30:1096–1106

    Article  PubMed  CAS  Google Scholar 

  10. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S (2012, March 1) Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma [Epub ahead of print]

  11. Duvic M, Becker JC, Dalle S, Vanaclocha F, Bernengo MG, Lebbe C, Dummer R, Hirawat S, Zhang L, Marshood M, Laird G, Prince HM (2008) Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). Blood 112:1005

    Article  Google Scholar 

  12. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68:805–813

    Article  PubMed  CAS  Google Scholar 

  13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry: Drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 12 June 2012

Download references

Acknowledgments

The authors would like to thank Moira Stewart (Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK), Suzanne Muir (Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK), Heather Charles (Charles River, Tranent, Edinburgh, UK), and Samit Hirawat (Novartis Oncology, Florham Park, NJ) for their contributions. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. We thank Kerry K. Brinkman, Ph.D. for medical editorial assistance with this manuscript. Funding for this study was provided by Novartis Pharmaceuticals Corporation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sally Clive.

Electronic supplementary material

Below is the link to the electronic supplementary material.

280_2012_1940_MOESM1_ESM.pdf

Online Resource 1. The cumulative excretion of radioactivity in urine (a) and feces (b) by percentage of dose following a single oral dose of 20 mg 14C-panobinostat for each patient over time. (●) denotes patient 1, (■) patient 2, (□) patient 3, and (▲) patient 4 (PDF 352 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clive, S., Woo, M.M., Nydam, T. et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70, 513–522 (2012). https://doi.org/10.1007/s00280-012-1940-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1940-9

Keywords

Navigation